New York City Metropolitan Area
Experienced, global, high energy finance leader with demonstrated success in various industries (LifeSciences/BioPharma/MedTech, Specialty/Industrial Chemicals, and Technology) and across companies at various stages (start up, high growth, early stage <$20M, small/medium <$500M, and medium/large >$1B).
CFO for middle market Private Equity portfolio company responsible for Finance, Accounting, Treasury, Human Resources, IT and Legal / Governance (9 Direct Reports, 50 FTE). -Implemented KPIs, metrics, and reporting packages that improved visibility and generated actionable insights for Executive Team and Board of Directors. -Strategic partner to and key member of Executive Team that delivered multiple value creation projects improving EBITDA and Cash Flow. -Other responsibilities include integration, bank and covenant reporting, treasury, data analytics, monthly close, budgeting and forecasting, organization design, and IT/ERP.
Business Unit Controller (Senior Director of Finance) for Global Chemicals Business Unit (Lab Products Group), which serves scientists to make the world cleaner, healthier, and safer. Senior Business Partner to VP/GM and cross functional management team, bringing strategic insight of business levers that impact financial performance, and solutions that maximize results. - Full P&L and Balance Sheet responsibility for global business, covering 6 key manufacturing and distribution centers, and multiple statutory entities around the world. - Responsible for all financial planning and reporting aspects of the business, including monthly / quarterly performance and forecasts, annual operating plan, and long range strategic planning. - Lead and develop a global finance team of >40 individuals.
Head of Finance / CFO for ATMI LifeSciences division, based outside of Brussels, Belgium. Partner with division leadership team to set strategic objectives and develop and execute initiatives on a regular basis to ensure they are achieved. Lead finance and accounting team to maintain US GAAP, SOx, and local statutory requirements in an efficient and effective manner. Significant business development activities including multiple acquisitions, minority equity investments, IP acquisitions, and a China based Joint Venture. Executive Team leader that maximized shareholder value through the divestiture and sale of the business at industry leading multiples. Led financial management presentations to potential suitors, and subsequent diligence and integration processes. Now part of Pall / Cytiva within Danaher LifeSciences.